Neurocrine price target raised to $165 from $160 at Barclays

Barclays raised the firm’s price target on Neurocrine (NBIX) to $165 from $160 and keeps an Overweight rating on the shares. The firm says Crenessity pricing is above expectations. It expects congenital adrenal hyperplasia sales estimates to be revised higher and looks for early indicators of uptake while the longer-term narrative develops.